Kunming, China – 20 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center publicized a batch of drug attribute changes on the provincial procurement platform, reclassifying five products from non‑essential‑drug status to essential drug (including former provincial‑supplement items) under the National Essential Medicines List (2026 Edition) and the Yunnan Provincial Supplemental Drug Catalog. Affected manufacturers must complete notification‑and‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) effective immediately, while objections must be lodged within five working days of the publicity date.

Policy Snapshot

Item	Detail
Agency	Yunnan Provincial Government Procurement and Transfer Center
Document	Publicity of Drug Attribute Changes for Platform‑Traded Products (annexed Attribute Change Table)
Basis	National Essential Medicines List (2026 Edition); Yunnan Provincial Supplemental Drug Catalog
Products Affected	5 – all reclassified from non‑essential drug to essential drug / former provincial supplement
Price & Registration Impact	Approval numbers unchanged; procurement price ceilings unchanged
Filing Obligation	Notification‑and‑commitment filing with Yunnan MPA, effective from the publicity date
Objection Window	5 working days from publicity (enterprises: 0871‑63606934, Drug & Device Procurement Section; public: 0871‑65330065, Comprehensive Supervision Section)
Filing Venue	Reception Hall, 1F, Yunnan Institute for Food and Drug Control and Testing – New Building, 616 Kefa Road, Kunming; Tel: 0871‑63112057

Products Reclassified

Product ID	Generic Name	Dosage Form	Specification	Manufacturer / Bidder	New Attribute
53521224	Cefradine for Injection	Injection	1.0 g (as C16H19N3O4S)	Shaanxi Dunsi Pharmaceutical Co., Ltd.	Former provincial supplement
53527176	Inosine Injection	Injection	2 ml : 0.1 g	Shaanxi Dunsi Pharmaceutical Co., Ltd. / Xi’an Tangchen Pharmaceutical Co., Ltd. (bidder)	Former provincial supplement
53526685	Pancreatin Enteric‑Coated Tablets	Enteric‑coated tablet	0.3 g × 24 tablets/box	Chongqing Tianzhi Pharmaceutical Co., Ltd.	Essential drug (NEML 2026)
53825865	Pancreatin Enteric‑Coated Tablets	Enteric‑coated tablet	0.3 g × 48 tablets/box	Chongqing Tianzhi Pharmaceutical Co., Ltd.	Essential drug (NEML 2026)
53501920	Longbishu Tablets	Sugar‑coated tablet	0.3 g core weight × 18 tablets/box	Qinhuangdao Da’en Pharmaceutical Co., Ltd.	Essential drug (NEML 2026)

Compliance Obligations & Procedure

• Notification‑and‑Commitment Filing: For products flagged “essential drug (incl. former provincial supplement)”, the filing process opens immediately. Enterprises must follow the requirements set out in the Yunnan MPA’s published announcement (mpa.yn.gov.cn, notice t20210917_1231876) and complete commitment‑based filing in person, bringing a printed copy of this publicity notice to the designated Yunnan MPA location.
• Consequences of Non‑Filing: Enterprises that fail to complete the notification‑and‑commitment filing bear full responsibility for the consequences, per the notice – a clear signal that platform trading status may hinge on timely compliance.
• Dual‑Track Objection Mechanism: Applicant enterprises with queries on the publicized information contact the Center’s Drug & Device Procurement Section (0871‑63606934); other enterprises or members of the public raising objections contact the Comprehensive Supervision Section (0871‑65330065) – both within five working days of the publicity date, with the publicized content open to general supervision.
• Administrative Continuity: Because drug approval numbers and procurement price ceilings remain unchanged, the reclassification is an attribute‑level adjustment rather than a repricing event – preserving existing commercial terms while altering catalog status.

Market Impact & Outlook

• NEML 2026 Alignment: Three of the five products (both Pancreatin SKUs and Longbishu Tablets) were upgraded directly under the National Essential Medicines List (2026 Edition), illustrating how provinces are synchronizing procurement‑platform attributes with the refreshed national catalog.
• Essential‑Drug Advantage: Essential‑drug designation typically carries policy preference in procurement and clinical use at public medical institutions – a status upgrade that can broaden access for the affected manufacturers’ products in Yunnan.
• Provincial‑Supplement Track: The two former provincial‑supplement items (Cefradine for Injection, Inosine Injection) reflect continued recognition of Yunnan’s supplemental catalog alongside the national list, per the notice’s stated basis.
• Tight Compliance Clock: With filing open “effective immediately” and only five working days to lodge objections, manufacturers must act within the same week to secure catalog status and avoid jeopardizing platform trading eligibility.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing outcomes, objection handling, catalog status, and platform trading eligibility for the five reclassified drug products in Yunnan Province. Actual results may differ due to risks including filing completion status, objection decisions, and subsequent policy adjustments by the Yunnan Provincial Government Procurement and Transfer Center and the Yunnan Provincial Medical Products Administration.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27877&CatalogId=3

Kunming, China – 07 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center has published the changes in drug attributes for online trading, covering 37 product entries realigned with the National Essential Drug List (2026 Edition), and announced that notification‑commitment filing (告知承诺备案) for essential‑drug status takes effect immediately for all listed products attributed as “Essential Drug (including former provincial supplement).”

Procurement Milestone

Item	Detail
Issuing Authority	Yunnan Provincial Government Procurement and Transfer Center
Notice Type	Public disclosure of drug attribute changes (online trading platform)
Policy Basis	National Essential Drug List (2026 Edition)
Scope	37 product entries across injectables, inhalation solutions, oral solids, TCM preparations and topical dosage forms
Disclosure Date	7 Sep 2026
Key Constants	Approval numbers unchanged; procurement ceiling prices unchanged for all entries
Filing Requirement	Notification‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) — effective immediately
Objection Window	5 business days from the disclosure date

Attribute Changes at a Glance

Category	Entries	Representative Products	Change
Essential‑drug status retained	32	Esomeprazole sodium for injection, ambroxol injection, milrinone injection, somatostatin for injection, nintedanib esylate soft capsules, cilostazol tablets, edaravone–dexborneol injection, ipratropium bromide inhalation solution (7 entries), azithromycin dry suspension	Essential drug → Essential drug (2026 List)
Upgraded to essential drug	3	Dalteparin sodium injection; nadroparin calcium injection (2 specs) — Yantai Dongcheng Northern Pharmaceutical	Non‑essential → Essential drug
Reclassified to former provincial supplement	2	Dengzhanxixin granules — Yunnan Plant Pharmaceutical	Essential drug → Former provincial supplement (原省补)

• Manufacturer Footprint: The batch spans roughly 20 producers, including Langtian Pharmaceutical (Hubei) (9 entries), Simcere Pharmaceutical, Chengdu Beit, Shaanxi Hanwang, and France‑based Laboratoire Unither, whose ipratropium bromide solution is bid through Sinopharm Distribution Center — evidence of continued import participation in Yunnan’s platform.

Essential Drug Filing Obligation

• Who Must Act: All enterprises whose products carry the “Essential Drug (including former provincial supplement)” attribute in the disclosure.
• Procedure: Complete the notification‑commitment filing per the Yunnan Provincial MPA’s published requirements, bringing a printed copy of this announcement to the designated filing site.
• Filing Site: Reception Hall, 1st Floor, Yunnan Institute for Food and Drug Control (new building, 616 Kefa Road, Kunming); filing hotline 0871‑63112057.
• Compliance Warning: Enterprises that fail to complete the filing bear the consequences — a clear signal that unfiled products risk losing essential‑drug procurement privileges on the platform.

Objection & Public Supervision

• Applicant Enterprises: Queries on the disclosed information must be raised within 5 business days to the Center’s Drug & Device Procurement Section (0871‑63606934).
• General Public & Third Parties: Objections to the disclosure are accepted within 5 business days by the Comprehensive Supervision Section (0871‑65330065), keeping the process open to public scrutiny.

Market Impact & Outlook

• 2026 List Alignment: This batch operationalizes the National Essential Drug List (2026 Edition) at the provincial trading level, with price ceilings and approval numbers held steady — suppliers gain attribute certainty without repricing risk.
• Anticoagulant Upgrade: The promotion of dalteparin and nadroparin from non‑essential to essential status strengthens the procurement position of Yantai Dongcheng Northern Pharmaceutical in Yunnan’s public‑hospital channel.
• TCM Reclassification: Moving dengzhanxixin granules to the “former provincial supplement” track preserves preferential treatment for legacy provincial items even after national‑list streamlining.
• Filing as Gatekeeper: The immediate‑effect notification‑commitment regime makes filing a de facto compliance checkpoint — enterprises should treat it as a short‑fuse administrative deadline tied directly to continued listing.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing completion, objection outcomes, and procurement treatment of the disclosed products. Actual results may differ due to risks including filing verification, third‑party objections, and subsequent announcements by the Yunnan Provincial MPA and the Center.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27813&CatalogId=3